AUCKLAND, Wednesday: BCG2 and research partner Clarity Insight have been appointed to work with the Neonatal Trust after a three-way competitive pitch. There was no incumbent – the trust has not previously worked with an agency.
BCG2 and Clarity Insight will help the trust achieve their ambitious goals to grow and support more families who have been thrust into the world of a Newborn Intensive Care Unit or Special Care Baby Unit with their little one.
Every year 10% of all babies are born prematurely in New Zealand. There are also full-term babies whose condition or illness requires admission to a NICU or SCBU after they are born. In all, over 5000 babies have a difficult to start life in New Zealand each year.
Initially made up of seven separate regional trusts, they are now a single NZ-wide team looking to grow so they can offer specialised support for parents experiencing a neonatal journey.
“Initially seven separate regional trusts, they are now a single team looking to grow so they can offer specialised support for parents experiencing a neonatal journey.”
BCG2 business director Alexia Walsh said: “As a business, we believe in ideas that make a difference.
“So working with the Neonatal Trust is a natural fit for us. The work they do is so important to help support the families of our most precious and vulnerable New Zealanders.
“We are humbled to be able to help this ‘miracles department’ to tell their story and grow.”
Neonatal Trust executive director Rachel Friend said: “We were looking to partner with an agency who understands our desire to make a significant difference in people’s lives and sees the opportunity to partner with a not-for-profit with the desire to become one of NZ’s most successful charities.”
Share this Post
The post BCG2 & Clarity Insight deliver a Miracle appeared first on M+AD!.
More Stories
By the Book: How ‘The Fugitive’ Director and an Investigative Journalist Collaborated on 2024’s Timeliest Thriller
The Best Holiday Ads of 2024
The Year in Ratings: How the Major News Outlets Performed in 2024